drugset
drugset / Trial / NCT03953742

Study of CPI-200 in Patients With Advanced Tumors

NCT03953742 ↗

Phase 1 Completed 17 enrolled Coordination Pharmaceuticals, Inc.
NaSequentialOpen-labelTreatment

Summary

This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify the maximum tolerated dose (MTD)

Timeline

Start
2019-07-01
Primary completion
2022-02-01
Completion
2022-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CPI-200 Unknown — Intravenous

Indications

No indication recorded.